Global vaccine alliance Gavi announced today that they’d provide the funds to develop Merck & Co.’s VSV-EBOV vaccine, to combat potential future Ebola outbreaks.
The $5 million U.S. deal for the experimental vaccine, originally developed in Canada, still needs the regulatory green light under the terms of the deal. Once it’s agreed to – and it should be – Merck hopes to have 300,000 doses ready for May. It’d first be used in expanded clinical trials and emergency use.
— Seth Berkley (@GaviSeth) January 20, 2016
“The most recent Ebola-related death in Sierra Leone and the fact that we know the reservoirs of Ebola still exist, underline why we must learn lessons from the devastating impact of the crisis and ensure we are better prepared for infectious disease outbreaks,” Gavi CEO Dr. Seth Berkley said in a release.
Gavi’s alliance includes the World Health Organization, UNICEF and World Bank, the vaccine industry, the Bill & Melinda Gates Foundation, and governments in developing countries, to name a few.